https://scholars.lib.ntu.edu.tw/handle/123456789/494882
標題: | Improving the anticancer effect of afatinib and microRNA by using lipid polymeric nanoparticles conjugated with dual pH-responsive and targeting peptides | 作者: | Hong S.-T Lin H Wang C.-S Chang C.-H Lin A.M.-Y CHIH-HSIN YANG Lo Y.-L. |
關鍵字: | Afatinib; Cell-penetrating peptides; Colorectal cancer; Epidermal growth factor receptor (EGFR); Nanoparticles; Targeting delivery | 公開日期: | 2019 | 出版社: | BioMed Central Ltd. | 卷: | 17 | 期: | 1 | 來源出版物: | Journal of Nanobiotechnology | 摘要: | Background: The emergence of resistance to chemotherapy or target therapy, tumor metastasis, and systemic toxicity caused by available anticancer drugs hamper the successful colorectal cancer (CRC) treatment. The rise in epidermal growth factor receptor (EGFR; human epidermal growth factor receptor 1; HER1) expression and enhanced phosphorylation of HER2 and HER3 are associated with tumor resistance, metastasis and invasion, thus resulting in poor outcome of anti-CRC therapy. The use of afatinib, a pan-HER inhibitor, is a potential therapeutic approach for resistant CRC. Additionally, miR-139 has been reported to be negatively correlated with chemoresistance, metastasis, and epithelial-mesenchymal transition (EMT) of CRC. Hence, we develop a nanoparticle formulation consisting of a polymer core to carry afatinib or miR-139, which is surrounded by lipids modified with a targeting ligand and a pH-sensitive penetrating peptide to improve the anticancer effect of cargos against CRC cells. Results: Our findings show that this formulation displays a spherical shape with core/shell structure, homogeneous particle size distribution and negative zeta potential. The prepared formulations demonstrate a pH-sensitive release profile and an enhanced uptake of cargos into human colorectal adenocarcinoma Caco-2 cells in response to the acidic pH. This nanoparticle formulation incorporating afatinib and miR-139 exhibits low toxicity to normal cells but shows a better inhibitory effect on Caco-2 cells than other formulations. Moreover, the encapsulation of afatinib and miR-139 in peptide-modified nanoparticles remarkably induces apoptosis and inhibits migration and resistance of Caco-2 cells via suppression of pan-HER tyrosine kinase/multidrug resistance/metastasis pathways. Conclusion: This study proposes a multifunctional nanoparticle formulation for targeted modulation of apoptosis/EGFR/HER/EMT/resistance/progression pathways to increase the sensitivity of colon cancer cells to afatinib. ? 2019 The Author(s). |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85070969171&doi=10.1186%2fs12951-019-0519-6&partnerID=40&md5=d33dd82ffcc0eb3a01bfbf04ea33c123 https://scholars.lib.ntu.edu.tw/handle/123456789/494882 |
ISSN: | 1477-3155 | DOI: | 10.1186/s12951-019-0519-6 | SDG/關鍵字: | Amino acids; Cell death; Chemotherapy; Controlled drug delivery; Diseases; Nanoparticles; Particle size; Particle size analysis; Pathology; Peptides; pH effects; pH sensors; RNA; Toxicity; Tumors; Afatinib; Cell-penetrating peptide; Colorectal cancer; Epidermal growth factor receptors; Targeting deliveries; Targeted drug delivery; afatinib; cell penetrating peptide; drug carrier; epidermal growth factor receptor; microRNA; nanoparticle; nanoshell; polymer; protein miR 139; unclassified drug; afatinib; antineoplastic agent; epidermal growth factor receptor; lipid; microRNA; nanoparticle; peptide; polymer; protein kinase inhibitor; animal cell; antineoplastic activity; apoptosis; Article; Caco-2 cell line; cancer inhibition; cell pH; colorectal carcinoma; drug conjugation; drug formulation; drug release; drug targeting; drug uptake; human; human cell; metastasis inhibition; migration inhibition; multidrug resistance; nanoencapsulation; nonhuman; particle size; protein synthesis inhibition; rat; zeta potential; animal; chemistry; colorectal tumor; drug effect; drug resistance; medicinal chemistry; metabolism; pH; procedures; Sprague Dawley rat; tumor cell line; Afatinib; Animals; Antineoplastic Agents; Apoptosis; Caco-2 Cells; Cell Line, Tumor; Chemistry, Pharmaceutical; Colorectal Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Hydrogen-Ion Concentration; Lipids; MicroRNAs; Nanoparticles; Peptides; Polymers; Protein Kinase Inhibitors; Rats; Rats, Sprague-Dawley |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。